Dr. Scott McComb
Research Officer, National Research Council of Canada; University of Ottawa
Email Address: email@example.com
Bio: Chimeric antigen receptor T cells (CAR-T) are an exciting new avenue to redirect immune cells to target and kill cancer. While breakthroughs in CAR-T therapy have led to life-saving treatments for patients with previously incurable leukemia, such therapies have been less successful against solid tumours. Moreover, the determinants of long term cancer regression in CAR-T treated patients are not yet well understood. Using genome editing, we are dissecting the mechanisms of programmed cell death and other immune signalling pathways in T cells in order to improve their effectiveness against cancer. Our long term goal is to create super-functional gene-edited cell therapies to treat currently intractable illnesses such as cancer and autoimmunity.